Literature DB >> 20640601

The clinical significance of MIB-1 labeling index in pituitary adenomas.

Geeta Chacko1, Ari G Chacko, Kalman Kovacs, Bernd W Scheithauer, Sunithi Mani, J P Muliyil, M S Seshadri.   

Abstract

Pituitary adenomas are unique in several ways--they are rarely malignant and yet can be invasive of several compartments. Recurrences in tumors with bland histological features that have been radically excised are a reason for frustration faced by endocrinologists and neurosurgeons in treatment of pituitary adenomas. Several attempts have therefore been made to determine the growth potential of pituitary adenomas. The aim of the present study was to define the biological significance of the MIB-1 labelling index (MIB-1 LI) in pituitary adenomas. The study included 159 cases of surgically treated pituitary adenoma seen in a single institution. MIB-1 LI was not found to be related to age or gender. The mean MIB-1 LI for clinically functional adenomas was marginally higher than that for clinically non-functional adenomas. There was a significant difference in the MIB-1 LI for tumors with a maximum diameter of more than 4 cm at a MIB-1 LI of ≥2%, however this difference was not statistically significant at a higher MIB-1 LI cut off value of >3%. The mean MIB-1 LI was significantly higher in tumors causing hydrocephalus and in those with cavernous sinus invasion and not when invasion was defined as invasion by tumor in any direction. We conclude that large pituitary macroadenomas, tumors filling the third ventricle causing hydrocephalus and tumors with true cavernous sinus invasions are more likely to have a higher proliferation index. Close follow up of tumors showing these imaging features would be recommended.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20640601     DOI: 10.1007/s11102-010-0242-7

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  46 in total

1.  Proliferation index of nonfunctioning pituitary adenomas: correlations with clinical characteristics and long-term follow-up results.

Authors:  M Losa; A Franzin; F Mangili; M R Terreni; R Barzaghi; F Veglia; P Mortini; M Giovanelli
Journal:  Neurosurgery       Date:  2000-12       Impact factor: 4.654

2.  p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions.

Authors:  K Thapar; B W Scheithauer; K Kovacs; P J Pernicone; E R Laws
Journal:  Neurosurgery       Date:  1996-04       Impact factor: 4.654

Review 3.  Epigenetic mechanisms of tumorigenesis.

Authors:  W E Farrell
Journal:  Horm Metab Res       Date:  2005-06       Impact factor: 2.936

4.  Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study.

Authors:  E Delgrange; J Trouillas; D Maiter; J Donckier; J Tourniaire
Journal:  J Clin Endocrinol Metab       Date:  1997-07       Impact factor: 5.958

5.  Proliferation, vascular endothelial growth factor expression and cavernous sinus invasion in growth hormone secreting pituitary adenomas.

Authors:  T Iuchi; N Saeki; K Osato; A Yamaura
Journal:  Acta Neurochir (Wien)       Date:  2000       Impact factor: 2.216

Review 6.  Pituitary tumours: findings from whole genome analyses.

Authors:  W E Farrell
Journal:  Endocr Relat Cancer       Date:  2006-09       Impact factor: 5.678

7.  Common genetic changes in hereditary and sporadic pituitary adenomas detected by comparative genomic hybridization.

Authors:  Svetlana D Pack; Liu-Xiu Qin; Evgenia Pak; Yun Wang; David O Ault; Poonam Mannan; Sivakumar Jaikumar; Constantine A Stratakis; Edward H Oldfield; Zhengping Zhuang; Robert J Weil
Journal:  Genes Chromosomes Cancer       Date:  2005-05       Impact factor: 5.006

8.  Proliferation activity in pituitary adenomas: measurement by monoclonal antibody Ki-67.

Authors:  E Knosp; K Kitz; A Perneczky
Journal:  Neurosurgery       Date:  1989-12       Impact factor: 4.654

9.  Giant pituitary tumors: a study based on surgical treatment of 118 cases.

Authors:  Atul Goel; Trimurti Nadkarni; Dattatraya Muzumdar; Ketan Desai; Umesh Phalke; Praveen Sharma
Journal:  Surg Neurol       Date:  2004-05

Review 10.  Ki-67 in pituitary neoplasms: a review--part I.

Authors:  Fateme Salehi; Anne Agur; Bernd W Scheithauer; Kalman Kovacs; Ricardo V Lloyd; Michael Cusimano
Journal:  Neurosurgery       Date:  2009-09       Impact factor: 4.654

View more
  10 in total

1.  The clinical and pathological significance of nitric oxide synthase in human pituitary adenomas: a comparison with MIB-1.

Authors:  K Onishi; T Kamida; Y Momii; T Abe; M Fujiki
Journal:  Endocrine       Date:  2013-09-06       Impact factor: 3.633

Review 2.  Clinical Impact of the Current WHO Classification of Pituitary Adenomas.

Authors:  W Saeger; J Honegger; M Theodoropoulou; U J Knappe; C Schöfl; S Petersenn; R Buslei
Journal:  Endocr Pathol       Date:  2016-06       Impact factor: 3.943

Review 3.  Radically resected pituitary adenomas: prognostic role of Ki 67 labeling index in a monocentric retrospective series and literature review.

Authors:  Sabrina Chiloiro; Antonio Bianchi; Francesco Doglietto; Chiara de Waure; Antonella Giampietro; Alessandra Fusco; Donato Iacovazzo; Linda Tartaglione; Francesco Di Nardo; Francesco Signorelli; Libero Lauriola; Carmelo Anile; Guido Rindi; Giulio Maira; Alfredo Pontecorvi; Laura De Marinis
Journal:  Pituitary       Date:  2014-06       Impact factor: 4.107

4.  Invasive adenoma and pituitary carcinoma: a SEER database analysis.

Authors:  Tara M Hansen; Sachin Batra; Michael Lim; Gary L Gallia; Peter C Burger; Roberto Salvatori; Gary Wand; Alfredo Quinones-Hinojosa; Lawrence Kleinberg; Kristin J Redmond
Journal:  Neurosurg Rev       Date:  2014-02-14       Impact factor: 3.042

5.  Identification of a subtype-specific ENC1 gene related to invasiveness in human pituitary null cell adenoma and oncocytomas.

Authors:  Jie Feng; Lichuan Hong; Yonggang Wu; Chuzhong Li; Hong Wan; Guilin Li; Yilin Sun; Shenyuan Yu; Prashant Chittiboina; Blake Montgomery; Zhengping Zhuang; Yazhuo Zhang
Journal:  J Neurooncol       Date:  2014-06-11       Impact factor: 4.130

6.  Correlation between histological subtypes and MRI findings in clinically nonfunctioning pituitary adenomas.

Authors:  Hiroshi Nishioka; Naoko Inoshita; Toshiaki Sano; Noriaki Fukuhara; Shozo Yamada
Journal:  Endocr Pathol       Date:  2012-09       Impact factor: 3.943

7.  Evaluation of prognostic utility of MIB-1 and p53 expression in pituitary adenomas: correlations with clinical behaviour and follow-up results.

Authors:  Asen Hadzhiyanev; Radina Ivanova; Emil Nachev; Atanaska Elenkova; Maria Yaneva; Sabina Zaharieva; Marin Marinov; Jivko Surchev; Asya Ivanova
Journal:  Biotechnol Biotechnol Equip       Date:  2014-08-22       Impact factor: 1.632

8.  Clinical neuropathology practice guide 3-2013: levels of evidence and clinical utility of prognostic and predictive candidate brain tumor biomarkers.

Authors:  Anna S Berghoff; Harald Stefanits; Adelheid Woehrer; Harald Heinzl; Matthias Preusser; Johannes A Hainfellner
Journal:  Clin Neuropathol       Date:  2013 May-Jun       Impact factor: 1.368

9.  The Past, Present, and Future Statuses of Formerly Classified "Atypical Pituitary Adenomas": A Clinicopathological Assessment of 101 Cases in a Cohort of More than 1,000 Pure Endoscopically Treated Patients in Single Center.

Authors:  Ercan Bal; İbrahim Kulaç; Selim Ayhan; Figen Söylemezoğlu; Mustafa Berker
Journal:  J Neurol Surg B Skull Base       Date:  2020-02-20

10.  Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors.

Authors:  Yu Mei; Wenya Linda Bi; Noah F Greenwald; Ziming Du; Nathalie Y R Agar; Ursula B Kaiser; Whitney W Woodmansee; David A Reardon; Gordon J Freeman; Peter E Fecci; Edward R Laws; Sandro Santagata; Gavin P Dunn; Ian F Dunn
Journal:  Oncotarget       Date:  2016-11-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.